Lesson
Diagnose a Pattern Across Time and Place
ADHD is a neurodevelopmental disorder defined by persistent symptoms, childhood onset, more than one setting, and meaningful impairment. It is not a synonym for distraction or productivity difficulty.
- DSM criteria
- Onset
- Settings
- Impairment
- Adult ADHD
diagnosis lifespan
Connect neurobiology, daily function, treatment exposure, and safety.
Confirm the symptom threshold
Children through age 16 generally require at least six symptoms in an applicable domain, while people age 17 and older generally require at least five. Symptoms persist for at least six months and are inconsistent with developmental level.
Prove onset and distribution
Several symptoms must have been present before age 12, and symptoms must be evident in at least two settings such as home, school, work, or relationships.
Document impairment
Symptoms must interfere with or reduce the quality of social, academic, or occupational function. Capability during a highly preferred activity does not exclude ADHD.
Diagnose adults longitudinally
Adult evaluation reconstructs childhood evidence, current demands, compensatory strategies, and impairment while testing newer causes of concentration difficulty.
Quick check
Lesson
Test the Alternatives Before Treating
Attention and impulse control are vulnerable to sleep loss, mood disorders, trauma, substances, learning demands, medical disease, and medication effects.
- Differential
- Comorbidity
- Cardiac history
- Growth
- Sleep
differential baseline
Connect neurobiology, daily function, treatment exposure, and safety.
Screen broadly
Assess anxiety, depression, bipolar disorder, trauma, psychosis, substance use, learning and language disorders, autism, tics, sleep apnea, seizure disorders, thyroid disease, sensory impairment, and medication effects.
Use collateral evidence
Parents, teachers, partners, school records, and prior evaluations can reveal setting specific demands, compensation, developmental onset, and alternative explanations.
Establish safety measures
Record blood pressure, pulse, weight, height and growth trajectory in children, sleep, appetite, psychiatric history, seizure history, substance exposure, and current medications.
Use cardiac testing selectively
Obtain personal and family cardiac history and perform an examination. ECG or cardiology evaluation follows concerning findings rather than a universal routine requirement.
Quick check
Lesson
Change the Environment as Well as the Prescription
ADHD care includes parent training, classroom interventions, organizational systems, accommodations, sleep, exercise, and explicit functional goals.
- Parent training
- Classroom
- Accommodation
- Skills
- Sleep
behavior environment
Connect neurobiology, daily function, treatment exposure, and safety.
Start appropriately in preschool
For children age four to five, evidence based parent training in behavior management and classroom interventions are first line. Methylphenidate can be considered when these measures are insufficient and moderate to severe impairment persists.
Treat school as part of care
Behavioral classroom plans, clear instructions, task chunking, reduced distraction, movement opportunities, and legally appropriate accommodations can improve access to learning.
Build external executive function
Calendars, reminders, visual schedules, checklists, simplified workspaces, transition cues, and planned accountability reduce dependence on working memory.
Measure meaningful goals
Targets can include assignment completion, safe driving, medication organization, conflict reduction, punctuality, financial control, or consistent sleep rather than observer convenience alone.
Quick check
Lesson
Distinguish the Two Stimulant Families
Methylphenidate and amphetamine products both increase catecholamine signaling, but they do so through related rather than identical mechanisms and patients can respond differently.
- Dopamine
- Norepinephrine
- DAT
- NET
- Release
stimulant pharmacology
Connect neurobiology, daily function, treatment exposure, and safety.
Map methylphenidate
Methylphenidate primarily inhibits dopamine and norepinephrine transporters, increasing synaptic catecholamine availability in attention and executive control networks.
Map amphetamines
Amphetamines enter presynaptic neurons through monoamine transporters, alter vesicular storage and transporter direction, and increase dopamine and norepinephrine release in addition to reuptake effects.
Interpret the network
Goodnotes highlights altered recruitment of prefrontal, anterior cingulate, basal ganglia, and parietal networks. Group imaging findings inform biology but do not diagnose an individual.
Compare response empirically
A patient may respond well to one family and poorly to the other. Prior response, duration, adverse effects, comorbidity, formulation, and misuse risk guide the sequence.
Quick check
Lesson
Treat the Delivery System as Part of the Drug
ADHD products use beads, osmotic delivery, prodrugs, liquids, chewables, orally disintegrating tablets, and transdermal systems to shape onset and duration.
- Immediate release
- Extended release
- Prodrug
- Patch
- Food
formulation engineering
Connect neurobiology, daily function, treatment exposure, and safety.
Define the required window
Map morning preparation, school or work, homework, driving, meals, evening relationships, and sleep. Longer is not always better when appetite or insomnia limits exposure.
Verify manipulation rules
Some capsules can be opened and sprinkled while others cannot. Extended release tablets may need to remain intact, and transdermal systems have product specific wear and disposal instructions.
Avoid false milligram equivalence
Different extended release methylphenidate or amphetamine products can produce different exposure profiles at the same labeled milligram dose.
Read food and acidity instructions
Food can delay or alter selected products, and gastrointestinal pH or urinary pH can influence some amphetamine exposures. Follow current product labeling rather than class assumptions.
Quick check
Lesson
Titrate Toward Function With a Safety Ceiling
Medication titration is a structured experiment using target function, coverage, adverse effects, vital signs, growth, sleep, and reports from relevant settings.
- Target
- Dose
- Coverage
- Growth
- Vital signs
titration monitoring
Connect neurobiology, daily function, treatment exposure, and safety.
Set targets before dose changes
Choose observable outcomes and establish when and where impairment occurs. A rating scale can support measurement but should not replace narrative function.
Map time of effect
Record onset, peak, wear off, rebound, meals, sleep, and unprotected hours. This distinguishes insufficient dose from an unsuitable duration or untreated comorbidity.
Monitor common burdens
Track appetite, weight, height in children, abdominal symptoms, headache, irritability, anxiety, sleep, blood pressure, pulse, and new movement or psychiatric symptoms.
Reassess the diagnosis when needed
Poor response to adequate trials should prompt review of adherence, formulation, target, diagnosis, learning disorder, mood, sleep, substances, and environment before uncontrolled escalation.
Quick check
Lesson
Prescribe Benefit Without Exporting Harm
FDA requires class wide boxed warning language for misuse, abuse, addiction, overdose, and death. Diversion prevention is part of routine ADHD care.
- Schedule II
- Misuse
- Diversion
- Storage
- Disposal
stimulant stewardship
Connect neurobiology, daily function, treatment exposure, and safety.
Assess before and during treatment
Review personal and household substance use, prior nonmedical use, pressure to share, early refill patterns, lost prescriptions, escalating dose, and functional consequences.
Counsel without euphemism
Take exactly as prescribed, never share, do not use another person's medication, and do not crush, snort, inject, or combine with nonprescribed controlled substances.
Secure and count when appropriate
Store medication out of sight and inaccessible to children, visitors, roommates, and peers. Use a consistent inventory strategy when diversion risk is meaningful.
Dispose safely
Use drug take back options or current FDA disposal instructions for unused medication. Do not leave surplus stimulant in an accessible cabinet.
Quick check
Lesson
Use Atomoxetine as a Delayed CYP2D6 System
Atomoxetine is a selective norepinephrine reuptake inhibitor with delayed clinical benefit and exposure strongly influenced by CYP2D6 activity.
- NRI
- CYP2D6
- Phenoconversion
- Liver
- Suicidality
atomoxetine pgx
Connect neurobiology, daily function, treatment exposure, and safety.
Expect delayed benefit
Atomoxetine does not produce immediate stimulant like coverage. Improvement can continue over several weeks, so evaluation needs adequate time at an interpretable dose.
Account for CYP2D6
Poor metabolizers and patients taking strong CYP2D6 inhibitors such as fluoxetine or paroxetine can have higher exposure. Goodnotes emphasizes this pharmacogenomic pathway.
Monitor the full profile
Assess blood pressure, pulse, appetite, gastrointestinal effects, sleep, urinary retention or hesitation, sexual effects, mood, and pediatric suicidal thinking.
Recognize rare liver injury
New jaundice, dark urine, right upper quadrant symptoms, unexplained flu like illness, or marked laboratory injury requires urgent evaluation and product specific discontinuation guidance.
Quick check
Lesson
Reduce Adrenergic Noise Without Abrupt Withdrawal
Guanfacine extended release and clonidine extended release are central alpha2 agonists that can support ADHD treatment in selected patients.
- Alpha2A
- Sedation
- Bradycardia
- Hypotension
- Taper
alpha2 agonists
Connect neurobiology, daily function, treatment exposure, and safety.
Understand the role
Alpha2 agonists can be used alone or with a stimulant and may be attractive when tics, hyperarousal, sleep initiation, or stimulant adverse effects shape the plan.
Monitor hemodynamics
Sedation, dizziness, hypotension, bradycardia, and syncope risk require cautious titration and review of other sedating or blood pressure lowering drugs.
Do not substitute IR and ER blindly
Immediate release and extended release products have different labeling and kinetics. Verify the exact product and schedule.
Taper rather than stop abruptly
Abrupt discontinuation can produce rebound hypertension and sympathetic symptoms. Missed doses may require retitration according to labeling.
Quick check
Lesson
Update the Nonstimulant Map
Viloxazine extended release expands the current nonstimulant pathway beyond the older Goodnotes and RxPrep algorithms.
- Viloxazine
- Norepinephrine
- CYP1A2
- Suicidality
- Adults
viloxazine selection
Connect neurobiology, daily function, treatment exposure, and safety.
Place the indication correctly
Viloxazine extended release is FDA approved for ADHD in pediatric patients age six and older and in adults.
Use current safety labeling
The product carries a boxed warning for suicidal thoughts and behaviors. Monitor mood and behavior closely during initiation and dose changes.
Review interactions
Viloxazine is a strong CYP1A2 inhibitor and can alter exposure to sensitive CYP1A2 substrates. Review the full medication and caffeine context.
Separate it from atomoxetine
Both are nonstimulants with norepinephrine related effects, but their enzymes, titration, interactions, and labeling are different.
Quick check
Lesson
Individualize the Evidence Boundary
Age, tics, cardiovascular history, substance use, pregnancy, lactation, liver function, and psychiatric comorbidity change the treatment path.
- Preschool
- Tics
- Substance use
- Pregnancy
- Adults
special populations
Connect neurobiology, daily function, treatment exposure, and safety.
Do not overstate tic restrictions
Tics and Tourette syndrome are not blanket contraindications to every stimulant. Establish baseline burden, monitor change, and individualize the class or use an alpha2 agonist when appropriate.
Protect mood stability
Screen for bipolar disorder, psychosis, severe anxiety, trauma, and substance use. New mania or psychosis during therapy requires urgent reassessment.
Plan reproductive care
Review pregnancy and lactation evidence by product, the consequences of untreated impairment, and nonpharmacologic supports. Avoid obsolete pregnancy letter categories.
Treat substance risk without abandonment
Use careful diagnosis, nonstimulant options when appropriate, controlled dispensing, monitoring, and coordination rather than automatically denying all care.
Quick check
Lesson
Build a Longitudinal System Around the Patient
ADHD care succeeds when treatment improves the patient's chosen functions while adverse effects, misuse risk, comorbidity, and access remain visible.
- Function
- Coverage
- Safety
- Adherence
- Autonomy
integrated outcomes
Connect neurobiology, daily function, treatment exposure, and safety.
Use a shared functional dashboard
Track attention and impulsivity beside school or work completion, driving, relationships, organization, sleep, appetite, vital signs, growth, and quality of life.
Record medication exposure precisely
Document generic drug, exact formulation, dose, timing, food instructions, adherence, onset, wear off, response, adverse effects, and reason for change.
Revisit identity and preference
Avoid framing neurodivergence only as deficit. Discuss what the patient wants to change, what they value, and which supports preserve autonomy.
Plan transitions
Prepare for school changes, college, work, driving, insurance, controlled substance rules, pediatric to adult care, pregnancy, and changes in household access.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 100 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.